Alternative splicing in EMT and TGF-β signaling during cancer progression

被引:9
|
作者
Zhang, Ying E. [1 ,2 ]
Stuelten, Christina H. [1 ]
机构
[1] NCI, Lab Cellular & Mol Biol, Ctr Canc Res, Bethesda, MD 20892 USA
[2] NIH, Lab Cellular & Mol Biol, Ctr Canc Res, NCI, Bldg 37,RM 2056B, Bethesda, MD 20892 USA
基金
美国国家卫生研究院;
关键词
Alternative splicing; EMT; TGF-beta; splicing factor; PRE-MESSENGER-RNA; TO-MESENCHYMAL TRANSITION; GENOME-WIDE ANALYSIS; REGULATORY NETWORK; DRUG-RESISTANCE; BREAST-CANCER; P120; CATENIN; STEM-CELLS; HNRNP A1; BINDING;
D O I
10.1016/j.semcancer.2024.04.001
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Epithelial to mesenchymal transition (EMT) is a physiological process during development where epithelial cells transform to acquire mesenchymal characteristics, which allows them to migrate and colonize secondary tissues. Many cellular signaling pathways and master transcriptional factors exert a myriad of controls to fine tune this vital process to meet various developmental and physiological needs. Adding to the complexity of this network are post -transcriptional and post -translational regulations. Among them, alternative splicing has been shown to play important roles to drive EMT -associated phenotypic changes, including actin cytoskeleton remodeling, cellcell junction changes, cell motility and invasiveness. In advanced cancers, transforming growth factor- beta (TGF- beta ) is a major inducer of EMT and is associated with tumor cell metastasis, cancer stem cell self -renewal, and drug resistance. This review aims to provide an overview of recent discoveries regarding alternative splicing events and the involvement of splicing factors in the EMT and TGF- beta signaling. It will emphasize the importance of various splicing factors involved in EMT and explore their regulatory mechanisms.
引用
收藏
页码:1 / 11
页数:11
相关论文
共 50 条
  • [21] TGF-β signaling in cancer
    Gu, Shuchen
    Feng, Xin-Hua
    ACTA BIOCHIMICA ET BIOPHYSICA SINICA, 2018, 50 (10) : 941 - 949
  • [22] TGF-β Signaling in Cancer
    Syed, Viqar
    JOURNAL OF CELLULAR BIOCHEMISTRY, 2016, 117 (06) : 1279 - 1287
  • [23] TGF-β as Multifaceted Orchestrator in HCC Progression: Signaling, EMT, Immune Microenvironment, and Novel Therapeutic Perspectives
    Dituri, Francesco
    Mancarella, Serena
    Cigliano, Antonio
    Chieti, Annarita
    Giannelli, Gianluigi
    SEMINARS IN LIVER DISEASE, 2019, 39 (01) : 53 - 69
  • [24] Hexim-1 modulates androgen receptor and the TGF-β signaling during the progression of prostate cancer
    Mascareno, Eduardo J.
    Belashov, Ivan
    Siddiqui, M. A. Q.
    Liu, Fang
    Dhar-Mascareno, Manya
    PROSTATE, 2012, 72 (09): : 1035 - 1044
  • [25] Alterations in TGFβ signaling during prostate cancer progression
    Thompson-Elliott, Bethtrice
    Johnson, Rarnice
    Khan, Shafiq A.
    AMERICAN JOURNAL OF CLINICAL AND EXPERIMENTAL UROLOGY, 2021, 9 (04): : 318 - 328
  • [26] Somatostatin Inhibited the EMT of Pancreatic Cancer Cells by Mediating the TGF-β/Smad Signaling Pathway
    Zhou, Xuan
    Wang, Wenting
    Liu, Li
    DISCOVERY MEDICINE, 2023, 35 (179) : 1086 - 1092
  • [27] Targeting TGF-β signaling in cancer
    Katz, Lior H.
    Li, Ying
    Chen, Jiun-Sheng
    Munoz, Nina M.
    Majumdar, Avijit
    Chen, Jian
    Mishra, Lopa
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2013, 17 (07) : 743 - 760
  • [28] TGF-β signaling in cancer metastasis
    Xie, Feng
    Ling, Li
    van Dam, Hans
    Zhou, Fangfang
    Zhang, Long
    ACTA BIOCHIMICA ET BIOPHYSICA SINICA, 2018, 50 (01) : 121 - 132
  • [29] Targeting TGF-β Signaling in Cancer
    Colak, Selcuk
    ten Dijke, Peter
    TRENDS IN CANCER, 2017, 3 (01): : 56 - 71
  • [30] TGF-β Signaling in Bone Remodeling and Osteosarcoma Progression
    Lamora, Audrey
    Talbot, Julie
    Mullard, Mathilde
    Brounais-Le Royer, Benedicte
    Redini, Francoise
    Verrecchia, Franck
    JOURNAL OF CLINICAL MEDICINE, 2016, 5 (11)